| Similar Articles |
|---|
 |
The Motley Fool
February 28, 2008
Brian Lawler |
Too Much Hope in Human Genome Shares Human Genome announces its guidance for 2008. Investors, take note.   |
The Motley Fool
December 9, 2008
Brian Orelli |
Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences. |
The Motley Fool
August 30, 2007
Brian Lawler |
Human Genome Steps Forward Human Genome Sciences investors got good news as the drugmaker took a quicker-than-expected step in its journey to get its lead drug, hepatitis C treatment Albuferon, on the path to FDA approval. |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
The Motley Fool
February 27, 2009
Brian Orelli |
Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
December 15, 2009
Brian Orelli |
Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
October 31, 2007
Brian Lawler |
The Next Hepatitis C Blockbuster? Never before have there been so many new drugs in development to treat Hepatitis C. Which companies have the compounds most likely to win this race? Investors, take note. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
The Motley Fool
April 3, 2009
Brian Orelli |
Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
The Motley Fool
May 28, 2009
Brian Orelli |
How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now? |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
The Motley Fool
April 28, 2008
Brian Lawler |
Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another. |
Pharmaceutical Executive
December 1, 2006 |
Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
Bio-IT World
August 15, 2005
Kevin Davies |
Good Practices Key to Pharma Two leaders in the biopharma industry spoke at the National Press Club dinner. H. Thomas Watkins discussed the potential for a number of therapeutic drugs and targets. Howard Asher aimed to determine a best practices guide for IT in the industry. |
The Motley Fool
January 16, 2009
Brian Orelli |
Sealed Lips Don't Sink Ships At the JPMorgan health care conference, there's updates aplenty, but not for the most interesting stories. |
